- Report
- January 2024
- 395 Pages
Global
From €7209EUR$7,500USD£6,182GBP
- Report
- January 2024
- 200 Pages
Global
From €3989EUR$4,150USD£3,421GBP
- Drug Pipelines
- July 2019
- 345 Pages
Global
€21145EUR$22,000USD£18,133GBP
- Report
- September 2019
Global
From €5161EUR$5,370USD£4,426GBP
- Report
- January 2022
- 137 Pages
Global
From €4325EUR$4,500USD£3,709GBP
Banzel (rufinamide) is a medication used to treat seizures associated with Lennox-Gastaut Syndrome (LGS). It is a member of the class of drugs known as anticonvulsants, which work by decreasing abnormal electrical activity in the brain. Banzel is approved by the U.S. Food and Drug Administration (FDA) for use in adults and children four years of age and older. It is available as a tablet and an oral suspension.
Banzel is part of the Central Nervous System (CNS) drug market, which includes medications used to treat a variety of neurological conditions, such as epilepsy, Parkinson's disease, and Alzheimer's disease. CNS drugs are typically used to reduce symptoms and improve quality of life.
Some companies in the Banzel market include Eisai Co., Ltd., Sunovion Pharmaceuticals Inc., and UCB Pharma. Show Less Read more